Product Details
Eli Lilly in India: Rethinking the Joint Venture Strategy
Product Number:
9B04M016
Publication Date:
05/14/2004
Revised Date:
03/13/2017
(Format Change)
Length:
18
pages
(12 pages of text)
BestSeller:
2006-2018
Product Type:
Case (Field)
Source:
Ivey
Eli Lilly and Company is a leading U.S. pharmaceutical company. The new president of intercontinental operations is re-evaluating all of the company's divisions, including the joint venture with Ranbaxy Laboratories Limited, one of India's largest pharmaceutical companies. This joint venture has run smoothly for a number of years despite their differences in focus, but recently Ranbaxy was experiencing cash flow difficulties due to its network of international sales. In addition, the Indian government was changing regulations for businesses in India, and joining the World Trade Organization would have an effect on India's chemical and drug regulations. The president must determine if this international joint venture still fits Eli Lilly's strategic objectives.
Issues:
Disciplines:
General Management/Strategy,
International
Industries:
Manufacturing
Setting:
India/United States, Large, 2001
Intended Audience:
Undergraduate/MBA
Price:
$4.25 CAD / $4.25 USD Printed Copy
$3.75 CAD / $3.75 USD Permissions
$3.75 CAD / $3.75 USD Digital Download
You Might Also Like...
-
Bohas Alexandre, Pierre-Xavier Meschi
Publication Date: 6/25/2020
Length: 20 pages
-
Subhasis Ray, Pratima Bansal
Publication Date: 6/10/2020
Length: 11 pages
-
Prashant Salwan, Shailesh Pandey, Milind Marathe
Publication Date: 1/06/2020
Length: 11 pages